FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310811635> ?p ?o ?g. }

• W4310811635 endingPage "1212" @default.
• W4310811635 startingPage "1212" @default.
• W4310811635 abstract "Roxadustat and recombinant human erythropoietin (rhuEPO) have been approved for the treatment of renal anemia in patients undergoing dialysis. The comparison of risk of peritoneal dialysis (PD)-associated peritonitis between roxadustat and rhuEPO in PD patients remains uncertain. We aimed to compare the risk of PD-associated peritonitis between roxadustat and rhuEPO and examine possible modifiers for the comparison in PD patients.A total of 437 PD patients with renal anemia (defined as hemoglobin ≤10.0 g/dL) from 4 centers were selected. Participants were scheduled for follow-up every 1-3 months at each center. We compared differences in baseline characteristics by medication group and 1:1 matching group based on propensity scores. PD-associated peritonitis was defined according to the International Society for Peritoneal Dialysis guidelines. Univariable and multivariable Cox proportional hazard analyses were performed to compare the risk of PD-associated peritonitis between roxadustat and rhuEPO in PD patients. Propensity score matching method was used to examine the robustness of results.A total of 437 participants, including 291 in roxadustat group and 146 in rhuEPO group, were included in the current study, respectively. During a median follow-up of 13.0 (25th-75th, 10.0-15.0) months, PD-associated peritonitis occurred in 68 patients, including 26 of 291 (0.10 episodes per patient-year) patients in the roxadustat group and 42 of 146 (0.27 episodes per patient-year) patients in the rhuEPO group. Overall, compared to patients in the rhuEPO group, the roxadustat group (hazard ratio, 0.345; 95% confidence interval: 0.202-0.589) was associated with a lower risk of PD-associated peritonitis with adjustment of use of roxadustat medication, age, sex, hypertension status, diabetes status, dialysis vintage, serum potassium, hemoglobin, and albumin. Furthermore, the results were consistent with the propensity score analysis. None of the variables, including age, sex, body mass index, PD vintage, presence of residual renal function, hemoglobin, albumin, serum potassium, and C-reactive protein levels, significantly modified the associations.Our study demonstrated that compared with rhuEPO, roxadustat may reduce the risk of PD-associated peritonitis in PD patients, highlighting the importance of roxadustat for the prevention of PD-associated peritonitis in PD patients." @default.
• W4310811635 created "2022-12-18" @default.
• W4310811635 creator A5004726461 @default.
• W4310811635 creator A5018729969 @default.
• W4310811635 creator A5023986598 @default.
• W4310811635 creator A5024419650 @default.
• W4310811635 creator A5026454143 @default.
• W4310811635 creator A5029695887 @default.
• W4310811635 creator A5049341415 @default.
• W4310811635 creator A5058405148 @default.
• W4310811635 creator A5064871720 @default.
• W4310811635 creator A5076699095 @default.
• W4310811635 creator A5081812115 @default.
• W4310811635 creator A5083069101 @default.
• W4310811635 creator A5087064479 @default.
• W4310811635 creator A5089058450 @default.
• W4310811635 date "2022-11-01" @default.
• W4310811635 modified "2023-10-17" @default.
• W4310811635 title "Comparison of risk of peritoneal dialysis-associated peritonitis between roxadustat and recombinant human erythropoietin in peritoneal dialysis patients: a retrospective comparative cohort study" @default.
• W4310811635 cites W1970971661 @default.
• W4310811635 cites W1978563638 @default.
• W4310811635 cites W1993324234 @default.
• W4310811635 cites W2003318263 @default.
• W4310811635 cites W2005539293 @default.
• W4310811635 cites W2008946188 @default.
• W4310811635 cites W2021947467 @default.
• W4310811635 cites W2038355445 @default.
• W4310811635 cites W2041418689 @default.
• W4310811635 cites W2059305865 @default.
• W4310811635 cites W2065779229 @default.
• W4310811635 cites W2078721739 @default.
• W4310811635 cites W2080274549 @default.
• W4310811635 cites W2080674760 @default.
• W4310811635 cites W2111850449 @default.
• W4310811635 cites W2130575161 @default.
• W4310811635 cites W2133329058 @default.
• W4310811635 cites W2134053452 @default.
• W4310811635 cites W2142180796 @default.
• W4310811635 cites W2149472502 @default.
• W4310811635 cites W2153961042 @default.
• W4310811635 cites W2164204772 @default.
• W4310811635 cites W2469939151 @default.
• W4310811635 cites W2589709928 @default.
• W4310811635 cites W2707556819 @default.
• W4310811635 cites W2900639426 @default.
• W4310811635 cites W2944273720 @default.
• W4310811635 cites W2963534431 @default.
• W4310811635 cites W2964045421 @default.
• W4310811635 cites W3000064468 @default.
• W4310811635 cites W3017246079 @default.
• W4310811635 cites W3020865171 @default.
• W4310811635 cites W3112489277 @default.
• W4310811635 cites W3119118230 @default.
• W4310811635 cites W3147940220 @default.
• W4310811635 cites W3199229819 @default.
• W4310811635 cites W3211654710 @default.
• W4310811635 cites W4220978627 @default.
• W4310811635 cites W4225854107 @default.
• W4310811635 cites W4226161688 @default.
• W4310811635 cites W4285719527 @default.
• W4310811635 doi "https://doi.org/10.21037/atm-22-5050" @default.
• W4310811635 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36544662" @default.
• W4310811635 hasPublicationYear "2022" @default.
• W4310811635 type Work @default.
• W4310811635 citedByCount "0" @default.
• W4310811635 crossrefType "journal-article" @default.
• W4310811635 hasAuthorship W4310811635A5004726461 @default.
• W4310811635 hasAuthorship W4310811635A5018729969 @default.
• W4310811635 hasAuthorship W4310811635A5023986598 @default.
• W4310811635 hasAuthorship W4310811635A5024419650 @default.
• W4310811635 hasAuthorship W4310811635A5026454143 @default.
• W4310811635 hasAuthorship W4310811635A5029695887 @default.
• W4310811635 hasAuthorship W4310811635A5049341415 @default.
• W4310811635 hasAuthorship W4310811635A5058405148 @default.
• W4310811635 hasAuthorship W4310811635A5064871720 @default.
• W4310811635 hasAuthorship W4310811635A5076699095 @default.
• W4310811635 hasAuthorship W4310811635A5081812115 @default.
• W4310811635 hasAuthorship W4310811635A5083069101 @default.
• W4310811635 hasAuthorship W4310811635A5087064479 @default.
• W4310811635 hasAuthorship W4310811635A5089058450 @default.
• W4310811635 hasBestOaLocation W43108116351 @default.
• W4310811635 hasConcept C126322002 @default.
• W4310811635 hasConcept C141071460 @default.
• W4310811635 hasConcept C167135981 @default.
• W4310811635 hasConcept C17923572 @default.
• W4310811635 hasConcept C207103383 @default.
• W4310811635 hasConcept C2778248108 @default.
• W4310811635 hasConcept C2779056158 @default.
• W4310811635 hasConcept C2780199535 @default.
• W4310811635 hasConcept C44249647 @default.
• W4310811635 hasConcept C50382708 @default.
• W4310811635 hasConcept C71924100 @default.
• W4310811635 hasConcept C90924648 @default.
• W4310811635 hasConceptScore W4310811635C126322002 @default.
• W4310811635 hasConceptScore W4310811635C141071460 @default.
• W4310811635 hasConceptScore W4310811635C167135981 @default.
• W4310811635 hasConceptScore W4310811635C17923572 @default.
• W4310811635 hasConceptScore W4310811635C207103383 @default.

• next